General Information of Drug (ID: DMFC71L)

Drug Name
Clozapine
Synonyms
Asaleptin; CLOZARIL; Clorazil; Clozapin; Clozapina; Clozapinum; Fazaclo; Iprox; Leponex; Lepotex; Fazaclo ODT; C 6305; HF1854; Clopine (TN); Clozapina [INN-Spanish]; Clozapine(tautomer); Clozapinum [INN-Latin]; Clozaril (TN); Denzapine (TN); Fazaclo (TN); Froidir (TN); HF-1854; KS-1166; Klozapol (TN); LEX-123; LX 100-129; Leponex (TN); W-801; Zaponex (TN); Clozapine [USAN:INN:BAN]; Clozapine (JAN/USP/INN); 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1]
Treatment-refractory schizophrenia N.A. Investigative [2]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 326.8
Logarithm of the Partition Coefficient (xlogp) 3.1
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is rapidly and completely absorbed []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
55% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.5 mL/min/kg [5]
Elimination
0.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 8 (range 4 - 12) hours [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 45.89515 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.055% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.6 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0118 mg/mL [3]
Chemical Identifiers
Formula
C18H19ClN4
IUPAC Name
3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine
Canonical SMILES
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
InChI
InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
InChIKey
QZUDBNBUXVUHMW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
135398737
ChEBI ID
CHEBI:3766
CAS Number
5786-21-0
DrugBank ID
DB00363
TTD ID
D0Z1RV
VARIDT ID
DR00474
INTEDE ID
DR0363
ACDINA ID
D00145
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D4 receptor (D4R) TTE0A2F DRD4_HUMAN Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [9]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [12]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [13]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
14-3-3 protein theta OTWG7F3H 1433T_HUMAN Gene/Protein Processing [14]
2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP) OTB8HCED CN37_HUMAN Gene/Protein Processing [14]
26S proteasome non-ATPase regulatory subunit 14 (PSMD14) OTJWHMZ5 PSDE_HUMAN Gene/Protein Processing [14]
26S proteasome non-ATPase regulatory subunit 7 (PSMD7) OT7PZZ4K PSMD7_HUMAN Gene/Protein Processing [14]
26S proteasome regulatory subunit 6A (PSMC3) OTSKT0JI PRS6A_HUMAN Gene/Protein Processing [14]
26S proteasome regulatory subunit 8 (PSMC5) OTJOORMR PRS8_HUMAN Gene/Protein Processing [14]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Gene/Protein Processing [15]
3-hydroxyacyl-CoA dehydrogenase type-2 (HSD17B10) OT7RJON4 HCD2_HUMAN Gene/Protein Processing [14]
3-hydroxyanthranilate 3,4-dioxygenase (HAAO) OTK9Y6SG 3HAO_HUMAN Gene/Protein Processing [16]
5-hydroxytryptamine receptor 2A (HTR2A) OTWXJX0M 5HT2A_HUMAN Drug Response [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D4 receptor (D4R) DTT DRD4 1.90E-01 0.19 0.76
P-glycoprotein 1 (ABCB1) DTP P-GP 6.54E-01 1.95E-01 4.04E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 5.57E-01 -7.89E-02 -7.93E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 8.99E-01 4.59E-03 2.19E-02
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.46E-01 -6.63E-03 -4.49E-02
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 9.62E-01 2.57E-02 1.10E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.35E-01 2.78E-02 2.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clozapine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Clozapine and Mesoridazine. Schizophrenia [6A20] [18]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Clozapine and Thioridazine. Schizophrenia [6A20] [18]
Haloperidol DM96SE0 Major Additive hypotensive effects by the combination of Clozapine and Haloperidol. Schizophrenia [6A20] [19]
Risperidone DMN6DXL Major Additive hypotensive effects by the combination of Clozapine and Risperidone. Schizophrenia [6A20] [19]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Clozapine and Amisulpride. Schizophrenia [6A20] [20]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Clozapine and Pimozide. Schizophrenia [6A20] [21]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Clozapine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Antagonize the effect of Clozapine when combined with Bethanechol. Abnormal micturition [MF50] [22]
Midostaurin DMI6E0R Major Additive myelosuppressive effects by the combination of Clozapine and Midostaurin. Acute myeloid leukaemia [2A60] [23]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Clozapine and Idarubicin. Acute myeloid leukaemia [2A60] [23]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Clozapine and Daunorubicin. Acute myeloid leukaemia [2A60] [23]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Clozapine and Arn-509. Acute myeloid leukaemia [2A60] [18]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Clozapine and Gilteritinib. Acute myeloid leukaemia [2A60] [23]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Clozapine and Oliceridine. Acute pain [MG31] [24]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Clozapine and Scopolamine. Addictive disorder [6C50-6C5Z] [19]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Clozapine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [25]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Clozapine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [25]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Clozapine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Tacrine DM51FY6 Moderate Antagonize the effect of Clozapine when combined with Tacrine. Alzheimer disease [8A20] [26]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Clozapine and Memantine. Alzheimer disease [8A20] [19]
Galantamine DMEO794 Moderate Antagonize the effect of Clozapine when combined with Galantamine. Alzheimer disease [8A20] [26]
Rivastigmine DMG629M Moderate Antagonize the effect of Clozapine when combined with Rivastigmine. Alzheimer disease [8A20] [26]
Donepezil DMIYG7Z Moderate Antagonize the effect of Clozapine when combined with Donepezil. Alzheimer disease [8A20] [26]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Clozapine and Metronidazole. Amoebiasis [1A36] [27]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Clozapine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [28]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Clozapine and Trimethaphan. Aneurysm/dissection [BD50] [23]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Clozapine and Bepridil. Angina pectoris [BA40] [18]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Clozapine and Dronedarone. Angina pectoris [BA40] [18]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Clozapine and Amyl nitrite. Angina pectoris [BA40] [28]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Clozapine and Nifedipine. Angina pectoris [BA40] [28]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Clozapine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [18]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Clozapine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [18]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Clozapine and Cilostazol. Arterial occlusive disease [BD40] [18]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Clozapine and Posaconazole. Aspergillosis [1F20] [18]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Clozapine and Levalbuterol. Asthma [CA23] [29]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Clozapine and Terbutaline. Asthma [CA23] [30]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Clozapine and Pirbuterol. Asthma [CA23] [30]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Clozapine and Salbutamol. Asthma [CA23] [31]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Clozapine and Formoterol. Asthma [CA23] [30]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Clozapine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [18]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Clozapine caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [32]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Clozapine and Ofloxacin. Bacterial infection [1A00-1C4Z] [18]
Ciprofloxacin XR DM2NLS9 Major Decreased metabolism of Clozapine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [33]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Clozapine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [34]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Clozapine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [18]
Norfloxacin DMIZ6W2 Major Decreased metabolism of Clozapine caused by Norfloxacin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [33]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Clozapine and Levofloxacin. Bacterial infection [1A00-1C4Z] [18]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Clozapine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [18]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Clozapine and Telithromycin. Bacterial infection [1A00-1C4Z] [18]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Clozapine and Retigabine. Behcet disease [4A62] [18]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Clozapine and Loperamide. Bowel habit change [ME05] [35]
Eribulin DM1DX4Q Major Additive myelosuppressive effects by the combination of Clozapine and Eribulin. Breast cancer [2C60-2C6Y] [23]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Clozapine and Lapatinib. Breast cancer [2C60-2C6Y] [23]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Clozapine and Tamoxifen. Breast cancer [2C60-2C6Y] [18]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Clozapine and Toremifene. Breast cancer [2C60-2C6Y] [18]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Clozapine and Sotalol. Cardiac arrhythmia [BC9Z] [18]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Clozapine when combined with Acetylcholine. Cataract [9B10] [36]
PF-04449913 DMSB068 Major Additive myelosuppressive effects by the combination of Clozapine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [23]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Clozapine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [37]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Clozapine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [30]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Clozapine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [29]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Clozapine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [37]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Clozapine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [30]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Clozapine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [37]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Clozapine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [30]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Clozapine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [30]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Clozapine and Dihydrocodeine. Chronic pain [MG30] [38]
Anisindione DM2C48U Moderate Increased plasma concentration of Clozapine and Anisindione due to competitive binding of plasma proteins. Coagulation defect [3B10] [23]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Clozapine and Oxaliplatin. Colorectal cancer [2B91] [23]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Clozapine and Isoproterenol. Conduction disorder [BC63] [30]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Clozapine and Olopatadine. Conjunctiva disorder [9A60] [39]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Clozapine and Halothane. Corneal disease [9A76-9A78] [18]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Clozapine and Propofol. Corneal disease [9A76-9A78] [40]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Clozapine and Sevoflurane. Corneal disease [9A76-9A78] [18]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Clozapine and Alfentanil. Corneal disease [9A76-9A78] [24]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Clozapine and Remifentanil. Corneal disease [9A76-9A78] [24]
Arbutamine DMCY8AF Moderate Increased risk of rapid heart rate by the combination of Clozapine and Arbutamine. Coronary atherosclerosis [BA80] [41]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Clozapine and Probucol. Coronary atherosclerosis [BA80] [18]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Clozapine and Clofazimine. Crohn disease [DD70] [18]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Clozapine and Mifepristone. Cushing syndrome [5A70] [18]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Clozapine and Pasireotide. Cushing syndrome [5A70] [18]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Clozapine and Osilodrostat. Cushing syndrome [5A70] [18]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Clozapine and Ethanol. Cystitis [GC00] [39]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Clozapine and Cyclandelate. Dementia [6D80-6D8Z] [28]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Clozapine and Sertraline. Depression [6A70-6A7Z] [18]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Clozapine and Cyclobenzaprine. Depression [6A70-6A7Z] [19]
Paroxetine DM5PVQE Moderate Decreased metabolism of Clozapine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [42]
Duloxetine DM9BI7M Moderate Decreased metabolism of Clozapine caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [43]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Clozapine and Escitalopram. Depression [6A70-6A7Z] [18]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Clozapine and Doxepin. Depression [6A70-6A7Z] [25]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Clozapine and Esketamine. Depression [6A70-6A7Z] [27]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Clozapine and Nitroglycerin. Diabetic foot ulcer [BD54] [28]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Clozapine and Hyoscyamine. Digestive system disease [DE2Z] [19]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Clozapine and Mepenzolate. Digestive system disease [DE2Z] [19]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Clozapine and Oxybutynine. Discovery agent [N.A.] [19]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Clozapine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [44]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Clozapine and Meclizine. Dizziness and giddiness [MB48] [19]
Trihexyphenidyl DMB19L8 Moderate Antagonize the effect of Clozapine when combined with Trihexyphenidyl. Dystonic disorder [8A02] [45]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Clozapine and Deutetrabenazine. Dystonic disorder [8A02] [46]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Clozapine and Ingrezza. Dystonic disorder [8A02] [18]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Clozapine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [47]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Clozapine caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Cenobamate DM8KLU9 Moderate Decreased metabolism of Clozapine caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [48]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Clozapine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [45]
Timolol DM3NXRU Moderate Additive hypotensive effects by the combination of Clozapine and Timolol. Essential hypertension [BA00] [28]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Clozapine and Guanabenz. Essential hypertension [BA00] [28]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Clozapine and Ethacrynic acid. Essential hypertension [BA00] [23]
Bendroflumethiazide DM7EVLC Moderate Additive hypotensive effects by the combination of Clozapine and Bendroflumethiazide. Essential hypertension [BA00] [28]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Clozapine and Phenoxybenzamine. Essential hypertension [BA00] [28]
Guanethidine DM9NSWT Moderate Additive hypotensive effects by the combination of Clozapine and Guanethidine. Essential hypertension [BA00] [28]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Clozapine and Nicardipine. Essential hypertension [BA00] [28]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Clozapine and Mecamylamine. Essential hypertension [BA00] [28]
Benzthiazide DMQWZ0H Moderate Additive hypotensive effects by the combination of Clozapine and Benzthiazide. Essential hypertension [BA00] [28]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Clozapine and Nadolol. Essential hypertension [BA00] [28]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Clozapine and Solifenacin. Functional bladder disorder [GC50] [18]
Mirabegron DMS1GYT Moderate Decreased metabolism of Clozapine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [49]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Clozapine and Tolterodine. Functional bladder disorder [GC50] [19]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Clozapine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [50]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Clozapine and Pentamidine. Fungal infection [1F29-1F2F] [23]
Terbinafine DMI6HUW Moderate Decreased metabolism of Clozapine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [51]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Clozapine and Ketoconazole. Fungal infection [1F29-1F2F] [18]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Clozapine and Phentolamine. Gangrene [MC85] [28]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Clozapine and Propantheline. Gastric ulcer [DA60] [19]
Cimetidine DMH61ZB Moderate Decreased metabolism of Clozapine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [23]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Clozapine and Cisapride. Gastro-oesophageal reflux disease [DA22] [18]
Sunitinib DMCBJSR Major Additive myelosuppressive effects by the combination of Clozapine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [23]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Clozapine when combined with Isoflurophate. Glaucoma [9C61] [36]
Carteolol DMFMDOB Moderate Additive hypotensive effects by the combination of Clozapine and Carteolol. Glaucoma [9C61] [28]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Clozapine and Brimonidine. Glaucoma [9C61] [52]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Clozapine when combined with Pilocarpine. Glaucoma [9C61] [22]
Spironolactone DM2AQ5N Moderate Additive hypotensive effects by the combination of Clozapine and Spironolactone. Heart failure [BD10-BD1Z] [28]
Triamterene DM2HU9I Moderate Additive hypotensive effects by the combination of Clozapine and Triamterene. Heart failure [BD10-BD1Z] [28]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Clozapine and Prazosin. Heart failure [BD10-BD1Z] [28]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Clozapine and Eplerenone. Heart failure [BD10-BD1Z] [28]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Clozapine and Carvedilol. Heart failure [BD10-BD1Z] [28]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Clozapine and Chlorothiazide. Heart failure [BD10-BD1Z] [28]
Furosemide DMMQ8ZG Moderate Additive hypotensive effects by the combination of Clozapine and Furosemide. Heart failure [BD10-BD1Z] [28]
Amiloride DMRTSGP Moderate Additive hypotensive effects by the combination of Clozapine and Amiloride. Heart failure [BD10-BD1Z] [28]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Clozapine and Bumetanide. Heart failure [BD10-BD1Z] [28]
Hydroflumethiazide DMVPUQI Moderate Additive hypotensive effects by the combination of Clozapine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [28]
Digitoxin DMWVIGP Moderate Increased plasma concentration of Clozapine and Digitoxin due to competitive binding of plasma proteins. Heart failure [BD10-BD1Z] [23]
Rifampin DMA8J1G Moderate Increased metabolism of Clozapine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [53]
Cobicistat DM6L4H2 Moderate Decreased clearance of Clozapine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [54]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Clozapine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [55]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Clozapine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [56]
Etravirine DMGV8QU Moderate Decreased metabolism of Clozapine caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Clozapine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [18]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Clozapine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [18]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Clozapine caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [27]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Clozapine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [27]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Clozapine and Eprosartan. Hypertension [BA00-BA04] [28]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Clozapine and Acebutolol. Hypertension [BA00-BA04] [28]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Clozapine and Moexipril. Hypertension [BA00-BA04] [28]
Bisoprolol DM3UZ95 Moderate Additive hypotensive effects by the combination of Clozapine and Bisoprolol. Hypertension [BA00-BA04] [28]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Clozapine and Captopril. Hypertension [BA00-BA04] [28]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Clozapine and Penbutolol. Hypertension [BA00-BA04] [28]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Clozapine and Trandolapril. Hypertension [BA00-BA04] [28]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Clozapine and Methyldopa. Hypertension [BA00-BA04] [28]
Clonidine DM6RZ9Q Moderate Additive hypotensive effects by the combination of Clozapine and Clonidine. Hypertension [BA00-BA04] [28]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Clozapine and Losartan. Hypertension [BA00-BA04] [28]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Clozapine and Nebivolol. Hypertension [BA00-BA04] [28]
Nisoldipine DM7ISKJ Moderate Additive hypotensive effects by the combination of Clozapine and Nisoldipine. Hypertension [BA00-BA04] [28]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Clozapine and Levamlodipine. Hypertension [BA00-BA04] [28]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Clozapine and Fosinopril. Hypertension [BA00-BA04] [28]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Clozapine and Doxazosin. Hypertension [BA00-BA04] [28]
Verapamil DMA7PEW Moderate Additive hypotensive effects by the combination of Clozapine and Verapamil. Hypertension [BA00-BA04] [28]
Amlodipine DMBDAZV Moderate Additive hypotensive effects by the combination of Clozapine and Amlodipine. Hypertension [BA00-BA04] [28]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Clozapine and TAK-491. Hypertension [BA00-BA04] [28]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Clozapine and Pindolol. Hypertension [BA00-BA04] [28]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Clozapine and Fenoldopam. Hypertension [BA00-BA04] [28]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Clozapine and Indapamide. Hypertension [BA00-BA04] [28]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Clozapine and Benazepril. Hypertension [BA00-BA04] [28]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Clozapine and Trichlormethiazide. Hypertension [BA00-BA04] [28]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Clozapine and Labetalol. Hypertension [BA00-BA04] [28]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Clozapine and Diazoxide. Hypertension [BA00-BA04] [28]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Clozapine and Perindopril. Hypertension [BA00-BA04] [28]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Clozapine and Felodipine. Hypertension [BA00-BA04] [28]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Clozapine and Deserpidine. Hypertension [BA00-BA04] [28]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Clozapine and Telmisartan. Hypertension [BA00-BA04] [28]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Clozapine and Hydralazine. Hypertension [BA00-BA04] [28]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Clozapine and Lisinopril. Hypertension [BA00-BA04] [28]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Clozapine and Clevidipine butyrate. Hypertension [BA00-BA04] [28]
Potassium chloride DMMTAJC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Clozapine and Potassium chloride. Hypo-kalaemia [5C77] [58]
Givosiran DM5PFIJ Moderate Decreased metabolism of Clozapine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [59]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Clozapine and Belladonna. Infectious gastroenteritis/colitis [1A40] [19]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Clozapine and Amantadine. Influenza [1E30-1E32] [60]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Clozapine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [61]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Clozapine and Polyethylene glycol. Irritable bowel syndrome [DD91] [62]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Clozapine and Phenolphthalein. Irritable bowel syndrome [DD91] [18]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Clozapine and Clidinium. Irritable bowel syndrome [DD91] [19]
Physostigmine DM2N0TO Moderate Antagonize the effect of Clozapine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [26]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Clozapine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [21]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Clozapine and Crizotinib. Lung cancer [2C25] [23]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Clozapine and Porfimer Sodium. Lung cancer [2C25] [63]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Clozapine and Ceritinib. Lung cancer [2C25] [23]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Clozapine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [64]
Osimertinib DMRJLAT Major Additive myelosuppressive effects by the combination of Clozapine and Osimertinib. Lung cancer [2C25] [23]
Capmatinib DMYCXKL Moderate Decreased metabolism of Clozapine caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [65]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Clozapine and Selpercatinib. Lung cancer [2C25] [23]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Clozapine and Lumefantrine. Malaria [1F40-1F45] [27]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Clozapine and Halofantrine. Malaria [1F40-1F45] [66]
Chloroquine DMSI5CB Major Additive myelosuppressive effects by the combination of Clozapine and Chloroquine. Malaria [1F40-1F45] [23]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Clozapine and Hydroxychloroquine. Malaria [1F40-1F45] [23]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Clozapine and Quinine. Malaria [1F40-1F45] [18]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Clozapine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [23]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Clozapine and Vemurafenib. Melanoma [2C30] [18]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Clozapine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [67]
Propranolol DM79NTF Moderate Additive hypotensive effects by the combination of Clozapine and Propranolol. Migraine [8A80] [28]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Clozapine and Lasmiditan. Migraine [8A80] [68]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Clozapine and Flibanserin. Mood disorder [6A60-6E23] [69]
Doxylamine DMKOXFE Moderate Additive anticholinergic effects by the combination of Clozapine and Doxylamine. Morning sickness disorder [SC00] [19]
Panobinostat DM58WKG Major Additive myelosuppressive effects by the combination of Clozapine and Panobinostat. Multiple myeloma [2A83] [23]
Thalidomide DM70BU5 Major Increased risk of prolong QT interval by the combination of Clozapine and Thalidomide. Multiple myeloma [2A83] [23]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Clozapine and Siponimod. Multiple sclerosis [8A40] [27]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Clozapine and Fingolimod. Multiple sclerosis [8A40] [18]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Clozapine and Ozanimod. Multiple sclerosis [8A40] [70]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Clozapine when combined with Neostigmine. Myasthenia gravis [8C6Y] [71]
Pyridostigmine DM8HO1L Moderate Antagonize the effect of Clozapine when combined with Pyridostigmine. Myasthenia gravis [8C6Y] [71]
Edrophonium DMCRQHB Moderate Antagonize the effect of Clozapine when combined with Edrophonium. Myasthenia gravis [8C6Y] [71]
Ambenonium DMOP0BL Moderate Antagonize the effect of Clozapine when combined with Ambenonium. Myasthenia gravis [8C6Y] [71]
Rifabutin DM1YBHK Moderate Increased metabolism of Clozapine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [72]
Romidepsin DMT5GNL Major Additive myelosuppressive effects by the combination of Clozapine and Romidepsin. Mycosis fungoides [2B01] [23]
Nilotinib DM7HXWT Major Additive myelosuppressive effects by the combination of Clozapine and Nilotinib. Myeloproliferative neoplasm [2A20] [23]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Clozapine and Dasatinib. Myeloproliferative neoplasm [2A20] [23]
Modafinil DMYILBE Moderate Decreased metabolism of Clozapine caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [27]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Clozapine and Phenindamine. Nasopharyngitis [CA00] [19]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Clozapine and Promethazine. Nausea/vomiting [MD90] [19]
Rolapitant DM8XP26 Moderate Decreased metabolism of Clozapine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [73]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Clozapine and Cyclizine. Nausea/vomiting [MD90] [19]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Clozapine and Palonosetron. Nausea/vomiting [MD90] [18]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Clozapine and Metoclopramide. Nausea/vomiting [MD90] [74]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Clozapine and Granisetron. Nausea/vomiting [MD90] [18]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Clozapine and Dolasetron. Nausea/vomiting [MD90] [18]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Clozapine and Ondansetron. Nausea/vomiting [MD90] [18]
Thiethylperazine DMU3IET Moderate Additive anticholinergic effects by the combination of Clozapine and Thiethylperazine. Nausea/vomiting [MD90] [19]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Clozapine and Bupropion. Nicotine use disorder [6C4A] [18]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Clozapine and Entrectinib. Non-small cell lung cancer [2C25] [23]
Lorcaserin DMG6OYJ Moderate Increased risk of hyperprolactinemic effects by the combination of Clozapine and Lorcaserin. Obesity [5B80-5B81] [75]
Metolazone DMB39LO Moderate Additive hypotensive effects by the combination of Clozapine and Metolazone. Oedema [MG29] [28]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Clozapine and Polythiazide. Oedema [MG29] [28]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Clozapine and Levomethadyl Acetate. Opioid use disorder [6C43] [21]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Clozapine and Lofexidine. Opioid use disorder [6C43] [18]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Clozapine and Apraclonidine. Optic nerve disorder [9C40] [52]
Rucaparib DM9PVX8 Major Additive myelosuppressive effects by the combination of Clozapine and Rucaparib. Ovarian cancer [2C73] [23]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Clozapine and Pentazocine. Pain [MG30-MG3Z] [24]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Clozapine and Dextropropoxyphene. Pain [MG30-MG3Z] [76]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Clozapine and Butorphanol. Pain [MG30-MG3Z] [24]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Clozapine and Oxymorphone. Pain [MG30-MG3Z] [24]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Clozapine and Levorphanol. Pain [MG30-MG3Z] [24]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Clozapine and Dezocine. Pain [MG30-MG3Z] [24]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Clozapine and Flavoxate. Pain [MG30-MG3Z] [19]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Clozapine and Nalbuphine. Pain [MG30-MG3Z] [24]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Clozapine and Buprenorphine. Pain [MG30-MG3Z] [18]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Clozapine and Hydrocodone. Pain [MG30-MG3Z] [24]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Clozapine and Meperidine. Pain [MG30-MG3Z] [24]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Clozapine and Oxycodone. Pain [MG30-MG3Z] [24]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Clozapine and Triclabendazole. Parasitic worm infestation [1F90] [18]
Pergolide DM14MAE Moderate Antagonize the effect of Clozapine when combined with Pergolide. Parkinsonism [8A00] [77]
Opicapone DM1BKA6 Moderate Antagonize the effect of Clozapine when combined with Opicapone. Parkinsonism [8A00] [77]
Biperiden DME78OA Moderate Antagonize the effect of Clozapine when combined with Biperiden. Parkinsonism [8A00] [45]
Procyclidine DMHFJDT Moderate Antagonize the effect of Clozapine when combined with Procyclidine. Parkinsonism [8A00] [45]
Entacapone DMLBVKQ Moderate Antagonize the effect of Clozapine when combined with Entacapone. Parkinsonism [8A00] [77]
Levodopa DMN3E57 Moderate Antagonize the effect of Clozapine when combined with Levodopa. Parkinsonism [8A00] [77]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Clozapine and Pimavanserin. Parkinsonism [8A00] [18]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Clozapine when combined with Bromocriptine. Parkinsonism [8A00] [77]
Apomorphine DMX38HQ Moderate Antagonize the effect of Clozapine when combined with Apomorphine. Parkinsonism [8A00] [78]
Abametapir DM2RX0I Moderate Decreased metabolism of Clozapine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [79]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Clozapine and Lindane. Pediculosis [1G00] [80]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Clozapine and Methylscopolamine. Peptic ulcer [DA61] [19]
Esomeprazole DM7BN0X Moderate Increased metabolism of Clozapine caused by Esomeprazole mediated induction of CYP450 enzyme. Peptic ulcer [DA61] [81]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Clozapine and Famotidine. Peptic ulcer [DA61] [27]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Clozapine and Macimorelin. Pituitary gland disorder [5A60-5A61] [82]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Clozapine and Lefamulin. Pneumonia [CA40] [83]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Clozapine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [84]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Clozapine and Ritodrine. Preterm labour/delivery [JB00] [30]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Clozapine and Degarelix. Prostate cancer [2C82] [18]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Clozapine and Enzalutamide. Prostate cancer [2C82] [18]
Flutamide DMK0O7U Major Increased risk of prolong QT interval by the combination of Clozapine and Flutamide. Prostate cancer [2C82] [18]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Clozapine and Relugolix. Prostate cancer [2C82] [18]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Clozapine and Bicalutamide. Prostate cancer [2C82] [18]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Clozapine and Terazosin. Prostate hyperplasia [GA90] [28]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Clozapine and Levomepromazine. Psychotic disorder [6A20-6A25] [19]
Fluphenazine DMIT8LX Major Additive hypotensive effects by the combination of Clozapine and Fluphenazine. Psychotic disorder [6A20-6A25] [19]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Clozapine and Tolazoline. Pulmonary hypertension [BB01] [28]
Sorafenib DMS8IFC Major Increased risk of prolong QT interval by the combination of Clozapine and Sorafenib. Renal cell carcinoma [2C90] [23]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Clozapine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [85]
Neupro DMHEAB1 Moderate Antagonize the effect of Clozapine when combined with Neupro. Restless legs syndrome [7A80] [77]
Celecoxib DM6LOQU Moderate Decreased metabolism of Clozapine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [86]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Clozapine and Cyproheptadine. Rheumatoid arthritis [FA20] [19]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Clozapine and Fentanyl. Sensation disturbance [MB40] [24]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Clozapine and Sufentanil. Sensation disturbance [MB40] [24]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Clozapine and Vardenafil. Sexual dysfunction [HA00-HA01] [18]
Armodafinil DMGB035 Moderate Decreased metabolism of Clozapine caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
LEE011 DMMX75K Major Additive myelosuppressive effects by the combination of Clozapine and LEE011. Solid tumour/cancer [2A00-2F9Z] [23]
Epirubicin DMPDW6T Major Additive myelosuppressive effects by the combination of Clozapine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [23]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Clozapine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [18]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Clozapine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [18]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Clozapine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [23]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Clozapine and Pitolisant. Somnolence [MG42] [18]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Clozapine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [18]
Warfarin DMJYCVW Moderate Increased plasma concentration of Clozapine and Warfarin due to competitive binding of plasma proteins. Supraventricular tachyarrhythmia [BC81] [23]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Clozapine and Adenosine. Supraventricular tachyarrhythmia [BC81] [87]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Clozapine and Lenvatinib. Thyroid cancer [2D10] [23]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Clozapine and Papaverine. Tonus and reflex abnormality [MB47] [88]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Clozapine and Tizanidine. Tonus and reflex abnormality [MB47] [18]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Clozapine and Tacrolimus. Transplant rejection [NE84] [18]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Clozapine and Atropine. Unspecific substance harmful effect [NE6Z] [19]
Nalidixic acid DMRM0JV Major Decreased metabolism of Clozapine caused by Nalidixic acid mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [33]
Enoxacin DMYTE6L Major Decreased metabolism of Clozapine caused by Enoxacin mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [33]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Clozapine and Astemizole. Vasomotor/allergic rhinitis [CA08] [18]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Clozapine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [19]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Clozapine and Triprolidine. Vasomotor/allergic rhinitis [CA08] [19]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Clozapine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [19]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Clozapine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [19]
Trimeprazine DMEMV9D Major Additive myelosuppressive effects by the combination of Clozapine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [23]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Clozapine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [19]
Dexbrompheniramine DMKVWGE Moderate Additive anticholinergic effects by the combination of Clozapine and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [19]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Clozapine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [19]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Clozapine and Azatadine. Vasomotor/allergic rhinitis [CA08] [19]
Procainamide DMNMXR8 Major Additive myelosuppressive effects by the combination of Clozapine and Procainamide. Ventricular tachyarrhythmia [BC71] [23]
Propafenone DMPIBJK Major Additive myelosuppressive effects by the combination of Clozapine and Propafenone. Ventricular tachyarrhythmia [BC71] [23]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Clozapine and Flecainide. Ventricular tachyarrhythmia [BC71] [18]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Clozapine and Amiodarone. Ventricular tachyarrhythmia [BC71] [18]
⏷ Show the Full List of 316 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Aspartame E00402 134601 Flavoring agent
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Xylitol E00136 6912 Coating agent; Diluent; Emollient; Flavoring agent; Humectant
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clozapine 100 mg tablet 100 mg Disintegrating Oral Tablet Oral
Clozapine 25 mg tablet 25 mg Disintegrating Oral Tablet Oral
Clozapine 12.5 mg tablet 12.5 mg Disintegrating Oral Tablet Oral
Clozapine 150 mg tablet 150 mg Disintegrating Oral Tablet Oral
Clozapine 200 mg tablet 200 mg Disintegrating Oral Tablet Oral
Clozapine 100 mg tablet 100 mg Oral Tablet Oral
Clozapine 25 mg tablet 25 mg Oral Tablet Oral
Clozapine 200 mg tablet 200 mg Oral Tablet Oral
Clozapine 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 38).
2 Clozapine FDA Label
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
9 Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
10 Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
11 Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
12 Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos. 2013 Mar;41(3):651-8.
13 Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
14 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
15 Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 2005;5(5):298-304.
16 Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids. Toxicol Mech Methods. 2023 Jun;33(5):401-410. doi: 10.1080/15376516.2022.2156005. Epub 2022 Dec 19.
17 Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J. 2006 Jan-Feb;6(1):42-51. doi: 10.1038/sj.tpj.6500342.
18 Canadian Pharmacists Association.
19 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
20 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
23 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
24 Cerner Multum, Inc. "Canadian Product Information.".
25 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
26 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
27 Cerner Multum, Inc. "Australian Product Information.".
28 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
29 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
30 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
31 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
32 Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
33 Fuhr U, Anders EM, Mahr G, Sorgel F, Staid AH "Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro." Antimicrob Agents Chemother 36 (1992): 942-8. [PMID: 1510417]
34 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
35 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
36 Multum Information Services, Inc. Expert Review Panel.
37 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
38 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
39 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
40 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
41 Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
42 Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4. [PMID: 8466541]
43 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
44 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
45 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
46 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
47 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
48 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
49 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
50 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
51 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
52 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
53 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
54 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
55 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
56 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
57 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
58 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
59 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
60 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
61 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
62 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
63 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
64 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
65 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
66 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
67 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
68 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
69 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
70 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
71 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
72 Joos AA, Frank UG, Kaschka WP "Pharmacokinetic interaction of clozapine and rifampicin in a forensic patieint with an atypical mycobacterial infection." J Clin Psychopharmacol 18 (1998): 83-5. [PMID: 9472849]
73 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
74 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
75 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
76 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
77 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
78 Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
79 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
80 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
81 Frick A, Kopitz J, Bergemann N "Omeprazole reduces clozapine plasma concentrations. A case report." Pharmacopsychiatry 36 (2003): 121-3. [PMID: 12806570]
82 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
83 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
84 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
85 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
86 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
87 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
88 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]